ABT Stock - Abbott Laboratories
Unlock GoAI Insights for ABT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $41.95B | $40.11B | $43.65B | $43.08B | $34.61B |
| Gross Profit | $21.32B | $20.04B | $22.32B | $23.21B | $17.38B |
| Gross Margin | 50.8% | 50.0% | 51.1% | 53.9% | 50.2% |
| Operating Income | $6.83B | $6.43B | $8.36B | $9.20B | $5.29B |
| Net Income | $13.40B | $5.72B | $6.93B | $7.07B | $4.50B |
| Net Margin | 31.9% | 14.3% | 15.9% | 16.4% | 13.0% |
| EPS | $7.67 | $3.30 | $3.94 | $3.97 | $2.52 |
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 10th 2025 | The Benchmark Company | Initiation | Buy | $145 |
| July 18th 2025 | Jefferies | Upgrade | Buy | $145 |
| June 16th 2025 | Leerink Partners | Initiation | Market Perform | $143 |
| October 8th 2024 | Oppenheimer | Initiation | Outperform | $130 |
| September 19th 2024 | Piper Sandler | Initiation | Overweight | $131 |
| July 30th 2024 | Edward Jones | Downgrade | Hold | - |
| May 30th 2024 | Goldman | Initiation | Buy | $121 |
| July 21st 2023 | Wolfe Research | Upgrade | Peer Perform | - |
| May 30th 2023 | Morgan Stanley | Downgrade | Equal Weight | $112 |
| April 20th 2023 | Barclays | Reiterated | Overweight | $127← $125 |
| April 20th 2023 | Wolfe Research | Reiterated | Underperform | $103← $107 |
| April 20th 2023 | Bernstein | Reiterated | Outperform | $133← $132 |
| April 20th 2023 | JP Morgan | Reiterated | Overweight | $122← $118 |
| April 20th 2023 | Raymond James | Reiterated | Outperform | $123← $116 |
| April 20th 2023 | UBS | Reiterated | Buy | $130← $117 |
Earnings History & Surprises
ABTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 14, 2026 | — | — | — | — |
Q1 2026 | Jan 28, 2026 | $1.50 | — | — | — |
Q4 2025 | Oct 15, 2025 | $1.30 | $1.30 | 0.0% | = MET |
Q3 2025 | Jul 17, 2025 | $1.26 | $1.26 | 0.0% | = MET |
Q2 2025 | Apr 16, 2025 | $1.07 | $1.09 | +1.9% | ✓ BEAT |
Q1 2025 | Jan 22, 2025 | $1.34 | $1.34 | 0.0% | = MET |
Q4 2024 | Oct 16, 2024 | $1.20 | $1.21 | +0.8% | ✓ BEAT |
Q3 2024 | Jul 18, 2024 | $1.10 | $1.14 | +3.6% | ✓ BEAT |
Q2 2024 | Apr 17, 2024 | $0.95 | $0.98 | +2.6% | ✓ BEAT |
Q1 2024 | Jan 24, 2024 | $1.19 | $1.19 | 0.0% | = MET |
Q4 2023 | Oct 18, 2023 | $1.10 | $1.14 | +3.6% | ✓ BEAT |
Q3 2023 | Jul 20, 2023 | $1.04 | $1.08 | +3.8% | ✓ BEAT |
Q2 2023 | Apr 19, 2023 | $0.98 | $1.03 | +5.1% | ✓ BEAT |
Q1 2023 | Jan 25, 2023 | $0.90 | $1.03 | +14.4% | ✓ BEAT |
Q4 2022 | Oct 19, 2022 | $0.91 | $1.15 | +26.4% | ✓ BEAT |
Q3 2022 | Jul 20, 2022 | $1.13 | $1.43 | +26.5% | ✓ BEAT |
Q2 2022 | Apr 20, 2022 | $1.47 | $1.73 | +17.7% | ✓ BEAT |
Q1 2022 | Jan 26, 2022 | $1.21 | $1.32 | +9.1% | ✓ BEAT |
Q4 2021 | Oct 20, 2021 | $0.95 | $1.40 | +47.4% | ✓ BEAT |
Q3 2021 | Jul 22, 2021 | $1.01 | $1.17 | +15.8% | ✓ BEAT |
Latest News
Abbott Receives FDA Clearance And CE Mark For Amplatzer Piccolo Delivery System
📈 PositiveAbbott Hikes Quarterly Dividend From $0.59 To $0.63 Per Share
📈 PositiveAbbott Initiates Medical Device Correction For Certain FreeStyle Libre 3 And FreeStyle Libre 3 Plus Sensors In The U.S.; No Other Libre Family Sensors, Readers Or Apps Are Impacted; Co Continues To Produce Libre 3, Libre 3 Plus Sensors To Fulfill Replacement And New Orders, Does Not Expect Significant Supply Disruptions
➖ NeutralEQIX stock has given up its prior gain. Exact Sciences shares were trading higher after Abbott agreed to acquire the company for $105 per share in a deal valued at about $20 billion.
➖ NeutralExact Sciences rises as Abbott moves to buy cancer test maker for $21B
📈 PositiveExact Sciences shares are trading higher after Abbott agreed to acquire the company for $105 per share in a deal valued at about $20 billion.
📈 PositiveAbbott Signs Agreement To Acquire Exact Sciences For $105/Share At ~$20B Equity Value
📈 PositiveBTIG Reiterates Buy on Abbott Laboratories, Maintains $145 Price Target
📈 PositiveAbbott Laboratories shares are trading lower after Bloomberg reported the company is weighing a takeover of Exact Sciences.
📉 NegativeExact Sciences shares are trading higher after Bloomberg reported that Abbott is weighing a takeover of the company.
📈 PositiveExact Sciences jumps on report Abbott nears takeover
📈 PositiveUPDATE: 'Abbott Weighs Takeover of Cancer Test Maker Exact Sciences' - Bloomberg News
📈 PositiveTandem Diabetes Care Announces That Its t:slim X2 Insulin Pump With Control-IQ+ Automated Insulin Delivery Now Integrates With Abbott's Freestyle Libre 3 Plus CGM In The U.S.
📈 PositiveCORRECTION: Abbott Laboratories Reported Q3 2025 Results On Oct 15, 2025
➖ NeutralAbbott Says Walmart Is First U.S. Retailer To Sell Its Continuous Glucose Monitor Lingo In 3500 Stores Across The U.S.
📈 PositiveBarclays Maintains Overweight on Abbott Laboratories, Raises Price Target to $162
📈 PositiveRaymond James Maintains Outperform on Abbott Laboratories, Raises Price Target to $146
📈 PositiveEvercore ISI Group Maintains Outperform on Abbott Laboratories, Lowers Price Target to $142
➖ NeutralRBC Capital Reiterates Outperform on Abbott Laboratories, Maintains $147 Price Target
📈 PositiveWells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $146
📈 PositiveFrequently Asked Questions about ABT
What is ABT's current stock price?
What is the analyst price target for ABT?
What sector is Abbott Laboratories in?
What is ABT's market cap?
Does ABT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ABT for comparison